Abstract
Background: Berberine (BBR) is an isoquinoline alkaloid extracted from the Chinese medicine, exerting a variety of pharmacological effects. BBR is partially metabolized by cytochrome 3A4 (CYP3A4) in vivo. Some reports indicated that BBR could inhibit the activity of CYP3A4. However, the underlying mechanisms are not completely understood. CYP3A4 is reported to be transcriptionally regulated by two nuclear receptors, nuclear transcription X receptor (PXR) and constitutive androstane receptor (CAR), and degraded via the ubiquitin-proteasome system. Hence, we tried to explore the mechanisms of CYP3A4 inhibition on both transcriptive and protein levels.
Methods: Western Blot, RT-PCR and Co-immunoprecipitation were used to perform the experiments.
Results: Our results showed that BBR inhibited the transcription of CYP3A4 gene by downregulating PXR. In addition, BBR accelerated the degradation of CYP3A4 protein via polyubiquitination pathway.
Conclusion: These findings may lead to the determination of novel drug-drug interactions with BBR, and contribute to future clinical application of BBR.
Keywords: Berberine, CYP3A4, transcription, ubiquitination degradation, X receptor (PXR), RT-PCR.
Current Pharmaceutical Design
Title:The Intracellular Mechanism of Berberine-Induced Inhibition of CYP3A4 Activity
Volume: 27 Issue: 40
Author(s): Pan-Feng Feng, Long-Xun Zhu, Jing Jie, Peng-Xiang Yang and Xia Chen*
Affiliation:
- Department of Pharmacy, Affiliated Hospital 2 of Nantong University, and First People’s Hospital of Nantong City, Jiangsu Province, 226001,China
Keywords: Berberine, CYP3A4, transcription, ubiquitination degradation, X receptor (PXR), RT-PCR.
Abstract:
Background: Berberine (BBR) is an isoquinoline alkaloid extracted from the Chinese medicine, exerting a variety of pharmacological effects. BBR is partially metabolized by cytochrome 3A4 (CYP3A4) in vivo. Some reports indicated that BBR could inhibit the activity of CYP3A4. However, the underlying mechanisms are not completely understood. CYP3A4 is reported to be transcriptionally regulated by two nuclear receptors, nuclear transcription X receptor (PXR) and constitutive androstane receptor (CAR), and degraded via the ubiquitin-proteasome system. Hence, we tried to explore the mechanisms of CYP3A4 inhibition on both transcriptive and protein levels.
Methods: Western Blot, RT-PCR and Co-immunoprecipitation were used to perform the experiments.
Results: Our results showed that BBR inhibited the transcription of CYP3A4 gene by downregulating PXR. In addition, BBR accelerated the degradation of CYP3A4 protein via polyubiquitination pathway.
Conclusion: These findings may lead to the determination of novel drug-drug interactions with BBR, and contribute to future clinical application of BBR.
Export Options
About this article
Cite this article as:
Feng Pan-Feng, Zhu Long-Xun, Jie Jing, Yang Peng-Xiang and Chen Xia*, The Intracellular Mechanism of Berberine-Induced Inhibition of CYP3A4 Activity, Current Pharmaceutical Design 2021; 27 (40) . https://dx.doi.org/10.2174/1381612827666210715155809
DOI https://dx.doi.org/10.2174/1381612827666210715155809 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements